Phoenix Biosciences SA
8.3 FTEPhoenix Biosciences reported revenue of €1.30m for the 2025 financial year (annual accounts filed with the NBB on 26 Jun 2026), with 8.3 full-time equivalents.
The score of Phoenix Biosciences shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Phoenix Biosciences's annual accounts
| 2025 | |
|---|---|
| Revenue | €1.30m |
| Net result | −€2.81m |
| Equity | €3.68m |
| Cash | €4.65m |
| EBITDA | −€2.75m |
| Total assets | €8.11m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Jun 2026
Phoenix Biosciences's financial analysis
- Solvency45.4%sector median: 34.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Phoenix Biosciences
Phoenix Biosciences's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1027.640.071
- VAT number
- BE1027640071
- Peppol
- Registered · 0208:1027640071 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 15 Sep 2025
- Registered office
- 1400 Nivelles
- Size
- Micro · 8.3 FTE
- Latest accounts
- 2025 · filed on 26 Jun 2026
- Activity
- Manufacture of other pharmaceutical products (NACE 21209)
Phoenix Biosciences (SA) has been based in Nivelles since 2025, active in: manufacture of other pharmaceutical products. For 2025, it reports revenue of €1.30m, a net loss of €2.81m and equity of €3.68m. With 8.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 45.4%, above the median of its sector (34.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Phoenix Biosciences
Companies in the same business, of comparable size and area, outside its group.
- White Raven Manufacture of pharmaceutical preparations Liège · balance sheet €9.55m
- Etherna Immunotherapies Research and experimental development on natural sciences and engineering Niel · balance sheet €12.8m
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- ExoXpert Manufacture of pharmaceutical preparations Liège · balance sheet €2.05m
- Univercells Technologies Manufacture of other chemical products n.e.c. Nivelles · balance sheet €16.2m
- Shant Biotech Manufacture of basic pharmaceutical products Tubize · balance sheet €11.0m
- Cellistic Manufacture of pharmaceutical preparations Mont-Saint-Guibert · balance sheet €41.6m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
Frequently asked questions about Phoenix Biosciences
What is the revenue of Phoenix Biosciences?
According to the 2025 annual accounts filed with the NBB, the revenue of Phoenix Biosciences amounts to 1,297,381 €.
What is the VAT number of Phoenix Biosciences?
In Belgium, the VAT number is the company number prefixed with BE: BE1027640071 for Phoenix Biosciences, if the company is VAT-registered. Its company number (CBE) is 1027.640.071.
Where is the registered office of Phoenix Biosciences?
According to the CBE register, the registered office of Phoenix Biosciences is in 1400 Nivelles.
What is the equity of Phoenix Biosciences?
At the close of the 2025 financial year, the equity of Phoenix Biosciences amounts to 3,681,944 €, a solvency of 45.4% of total assets.
How many people work at Phoenix Biosciences?
8.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Phoenix Biosciences?
The register lists 8 active mandates at Phoenix Biosciences. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Phoenix Biosciences
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →